MapLight Therapeutics
MPLT
9.09
-0.27
-2.88%
MapLight Therapeutics
US · MPLT
#3723 by market cap
Listed 2025
9.09
-0.27
-2.88%
Live - 5344 symbols - heartbeat 250s ago
· 2026-10-08 10:00
Pre-market
9.06
-3.21%
After-hours
9.36
0.00%
Overnight
9.36
0.00%
- Market cap
- 505.18M
- P/E (TTM)i
- -1.80
- P/Bi
- 1.45
- EPSi
- -3.66
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on MPLT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 7.1 percentage points.
Institutional ownership
- Held by institutions
- 94.25% -7.06pp
- Institutions
- 126 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Private Company48.74%
VC/PE Fund18.98%
Mutual Fund18.84%
Public Company3.82%
Hedge Fund3.82%
Individual/Insider2.41%
Other3.34%
Top holders as of 2026-09-01
Catalyst4, Inc
45.54% · 25.31M sh
Forbion Capital Partners B.V.
7.97% · 4.43M sh
T. Rowe Price Group, Inc.
7.57% · 4.20M sh
Novo Holdings A/S
3.75% · 2.09M sh
Chen's Group International Limited
2.93% · 1.63M sh
Pivotal BioVenture Partners LLC
2.31% · 1.28M sh
The Goldman Sachs Group, Inc.
1.95% · 1.08M sh
BlackRock
1.84% · 1.03M sh
5AM Venture Management, LLC
1.71% · 950.01K sh
Sanofi
1.64% · 912.04K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Catalyst4, Inc | -- | 45.54% |
| Vishwas Setia | Chief Financial Officer | 0.64% |
| Erin Foff | Chief Medical Officer | 0.56% |
| Christopher Kroeger | Chief Executive Officer | 0.47% |
| Robert Malenka | Co-Founder, Director & Member of Scientific Advisory Board | 0.39% |
| Timothy Garnett | Independent Director | 0.12% |
| James Lillie | Chief Scientific Officer | 0.08% |
| George Pavlov | Independent Chairperson | 0.04% |
| Troy Cox | Independent Director | 0.04% |
| Anatol Kreitzer | Chief Discovery Officer | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | Kristopher Hanson | General Counsel | Automatic Disposition | -16,509 | $11.67 |
| 2026-08-16 | Christopher Kroeger | Chief Executive Officer | Other Acquisition | +23,145 | -- |
| 2026-08-16 | Christopher Kroeger | Chief Executive Officer | Other Derivative Acquisition | +93,955 | $11.25 |
| 2026-08-16 | Jonathan Gillis | Chief Administrative & Accounting Officer | Other Acquisition | +8,242 | -- |
| 2026-08-16 | Jonathan Gillis | Chief Administrative & Accounting Officer | Other Derivative Acquisition | +27,268 | $11.25 |
| 2026-08-16 | James Lillie | Chief Scientific Officer | Other Acquisition | +7,730 | -- |
| 2026-08-16 | James Lillie | Chief Scientific Officer | Other Derivative Acquisition | +31,395 | $11.25 |
| 2026-08-16 | Kristopher Hanson | General Counsel | Other Acquisition | +7,730 | -- |
| 2026-08-16 | Kristopher Hanson | General Counsel | Other Derivative Acquisition | +31,395 | $11.25 |
| 2026-08-16 | Erin Foff | Chief Medical Officer | Other Acquisition | +13,360 | -- |
| 2026-08-16 | Erin Foff | Chief Medical Officer | Other Derivative Acquisition | +54,240 | $11.25 |
| 2026-08-16 | Anatol Kreitzer | Chief Discovery Officer | Other Acquisition | +6,020 | -- |
| 2026-08-16 | Anatol Kreitzer | Chief Discovery Officer | Other Derivative Acquisition | +24,455 | $11.25 |
| 2026-08-13 | Catalyst4, Inc | -- | Open Market Acquisition | +4,400,000 | $11.38 |
| 2026-08-13 | Catalyst4, Inc | -- | Open Market Derivative Acquisiti | +2,928,686 | $0.00 |
| 2026-08-02 | James Lillie | Chief Scientific Officer | Automatic Disposition | -22,082 | $12.54 |
| 2026-07-29 | Novo Holdings A/S | -- | Intent to Sell (Form 144) | -1,600,000 | $15.02 |
| 2026-07-29 | Catalyst4, Inc | -- | Private Acquisition | +1,000,000 | $13.00 |
| 2026-07-28 | Catalyst4, Inc | -- | Open Market Acquisition | +209,225 | $10.74–12.63 |
| 2026-07-27 | Troy Cox | Independent Director | Open Market Acquisition | +15,620 | $9.52 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:31 · For reference only, not investment advice and not tailored to your situation.